Confirmatory Testing for Onychomycosis—Reply
View/ Open
Published Version
https://doi.org/10.1001/jamadermatol.2016.0784Metadata
Show full item recordCitation
Mikailov, Anar, Cara Joyce, and Arash Mostaghimi. 2016. “Confirmatory Testing for Onychomycosis—Reply.” JAMA Dermatology 152 (7) (July 1): 848. doi:10.1001/jamadermatol.2016.0784.Abstract
In Reply We thank Wang et al and Lipner and Scher for their interest in our study and agree with both groups about other potential consequences of terbinafine use.1 Our analysis of the adverse effects of terbinafine included only hepatic manifestations, given the US Food and Drug Administration and package insert recommendations to check transaminases prior to initiation of therapy and the availability of reliable incidence statistics from the National Library of Medicine LiverTox database. The other adverse effects mentioned by Wang et al and Lipner and Scher are certainly important; incidence statistics are not available for those adverse events, however, limiting our ability to perform a similar analysis. Nevertheless, we emphasize shared decision making with patients before prescribing systemic medications with the potential for idiosyncratic adverse drug reactions.Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:33785924
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)